Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. Kato K, et al. Among authors: motoyama s. Esophagus. 2023 Apr;20(2):291-301. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19. Esophagus. 2023. PMID: 36401133 Free PMC article. Clinical Trial.
Appropriateness of the institute certification system for esophageal surgeries by the Japan Esophageal Society: evaluation of survival outcomes using data from the National Database of Hospital-Based Cancer Registries in Japan.
Motoyama S, Maeda E, Yano M, Yasuda T, Ohira M, Doki Y, Toh Y, Higashi T, Matsubara H; Japan Esophageal Society. Motoyama S, et al. Esophagus. 2019 Jan;16(1):114-121. doi: 10.1007/s10388-018-0646-4. Epub 2018 Oct 15. Esophagus. 2019. PMID: 30324431 Free PMC article.
Impact of certification status of the institute and surgeon on short-term outcomes after surgery for thoracic esophageal cancer: evaluation using data on 16,752 patients from the National Clinical Database in Japan.
Motoyama S, Yamamoto H, Miyata H, Yano M, Yasuda T, Ohira M, Kajiyama Y, Toh Y, Watanabe M, Kakeji Y, Seto Y, Doki Y, Matsubara H. Motoyama S, et al. Esophagus. 2020 Jan;17(1):41-49. doi: 10.1007/s10388-019-00694-9. Epub 2019 Oct 3. Esophagus. 2020. PMID: 31583502 Free PMC article.
Esophagectomy performed at institutes certified by the Japan Esophageal Society provide long-term survival advantages to esophageal cancer patients: second report analyzing 4897 cases with propensity score matching.
Motoyama S, Maeda E, Yano M, Yasuda T, Ohira M, Kajiyama Y, Higashi T, Doki Y, Matsubara H. Motoyama S, et al. Esophagus. 2020 Apr;17(2):141-148. doi: 10.1007/s10388-019-00712-w. Epub 2020 Jan 14. Esophagus. 2020. PMID: 31939000 Free PMC article.
Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3).
Takahashi M, Kato K, Okada M, Chin K, Kadowaki S, Hamamoto Y, Doki Y, Kubota Y, Kawakami H, Ogata T, Hara H, Muto M, Nakashima Y, Ishihara R, Tsuda M, Motoyama S, Kodani M, Kitagawa Y. Takahashi M, et al. Among authors: motoyama s. Esophagus. 2021 Jan;18(1):90-99. doi: 10.1007/s10388-020-00794-x. Epub 2020 Nov 10. Esophagus. 2021. PMID: 33170461 Free PMC article. Clinical Trial.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Kelly RJ, et al. Among authors: motoyama s. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. N Engl J Med. 2021. PMID: 33789008 Clinical Trial.
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Doki Y, et al. Among authors: motoyama s. N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380. N Engl J Med. 2022. PMID: 35108470 Clinical Trial.
A Multi-institutional Study to Diagnose the Risk of Lymph Node Metastasis Using a CRP Genetic Polymorphism Test Kit in pT1, cN0 Thoracic Esophageal Squamous Cell Carcinoma.
Motoyama S, Hosaka M, Kamei T, Ueno M, Watanabe M, Ohkura YU, Mine S, Tanabe S, Toyokawa T, Wakita A, Nishikawa K, Ninomiya I, Fujita K, Kanda M, Hirai M, Hoshi M, Chiu SW, Takata M, Yamaguchi T, Miura M. Motoyama S, et al. Anticancer Res. 2022 Dec;42(12):6105-6112. doi: 10.21873/anticanres.16123. Anticancer Res. 2022. PMID: 36456128
339 results